Published May 1, 2011 | Version v1
Journal article

Role of Radiotherapy as Curative Treatment of Extramammary Paget's Disease

  • 1. Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa (Japan)
  • 2. Department of Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa (Japan)
  • 3. Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa (Japan)
  • 4. Department of Radiation Oncology, Yokohama City University Medical Center, Yokohama, Kanagawa (Japan)

Description

Purpose: Extramammary Paget's disease (EMPD) is a relatively rare malignancy that usually arises in the genital areas. Wide surgical excision remains the standard and most reliable curative treatment of EMPD. However, surgery is sometimes not possible, because many patients are elderly, and complete excision can be difficult owing to the tumor location. We, therefore, performed a review to determine the role of radiotherapy (RT) for EMPD. Methods and Materials: A total of 22 patients with EMPD in their external genitalia (4 men and 18 women, age 52-94 years at RT) underwent RT with curative intent. Nine patients had regional lymph node metastases. A total dose of 45-70.2 Gy (median, 60) was delivered to the pelvis, including the tumors, in 25-39 fractions (median, 33). Results: In all but 3 patients, the irradiated tumors were controlled during a follow-up period of 8-133 months (median, 42). Of the 22 patients, 13 developed recurrences, including local progression within the radiation field in 3 and lymph node and/or distant metastases outside the radiation field in 10, at 3-43 months after treatment. The 2- and 5-year local progression-free rates were 91% and 84%, respectively. Of the 22 patients, 7 patients had died at 33-73 months after RT. The cause of death was tumor progression in 4, infectious pneumonia in 2, and renal failure in 1 patient. The overall and cause-specific survival rates were 100% for both at 2 years and 53% and 73% at 5 years, respectively. No therapy-related Grade 3 or greater toxicity was observed. Conclusions: RT is safe and effective for patients with EMPD. It appears to contribute to prolonged survival as a result of good tumor control.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2010.01.073

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2010.01.073;
PII
S0360-3016(10)03028-2;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
80
Journal Issue
1
Journal Page Range
p. 47-54
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
42083386
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
FAILURES; FEMALE GENITALS; KIDNEYS; LYMPH NODES; MALE GENITALS; METASTASES; NEOPLASMS; PELVIS; PNEUMONIA; RADIOTHERAPY; SURVIVAL CURVES
Descriptors DEC
BODY; DISEASES; LYMPHATIC SYSTEM; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RESPIRATORY SYSTEM DISEASES; THERAPY

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.